Feeding village children in Mindanao Philippines and watching my boy and girl grow up.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree. BP has lobbying power we never will have and imo LL will survive probably after being scooped up by one of them. Anyone interested in LL has more bargaining power after recent events.
The symbol for criis and opportunity in Japan are the same. When I was a broker I used to have that symbol on my office wall.
There can be 1000 people here with a thousand shares each who may want to vote him out but reality is that the whales will decide. They own millions of shares. It's not going to happen imo.
So a person with 1 share gets the same vote as a person with a million shares? It does not work that way. Each share is a vote
Misiu. She had technical issues so I did it.
Science is solid. Leronlimab is a diamond not CZ.
I will let the RSI dictate when to add.
He meant he was not paid to do the podcast. And during the podcast it was stayed that he had no shares.
Agree. It pays to be diplomatic.
Big Pharm has something we do not....lobbying power. If one wishes to get upset they should be upset with the systemic problem that has been in place for decades. Imo.
Does Leronlimab cure headaches? Because Tylenol is doing nothing for this whopper I've got.
We get a fee.
Comfortably above it. Making a higher high above .3352 and closing there. I will add if we close at .34 or higher.
My pleasure.
I annotated the chart the other day bexause I too was apprehensive about the RSI, but it is showing strength in an attempt to break that downtrend line despite the over bought RSI.
In this chart I highlighted with red lines ehen the RSI was at 90 (as it is now). If you look at June, 2016 the RSI hit 90 but corrected as the pps continued to climb through Feb, 2017 going to over $1.00 before correcting.
Important to me is the downtrend line which we tested yesterday and today. When we break it I will add to my position despite the overbought RSI
https://stockcharts.com/h-sc/ui?s=TBPMF&p=D&yr=10&mn=3&dy=10&id=p03611140282&a=943308763&listNum=1
So if a person dies before the ambulance arrives at the house it is the paramedics fault?
That is the analogy you ate making.
That ship sailed a long time ago.
Warrants can not vote stock can. Hmmmm..
Great post. Glad to see u here. Look for u and Misiu's posts.
Enlighten me. What material information has he disclosed?
That is an explicitly well written and emotionally charged depiction of your experience and emotions with a happy ending that you are fortunate to have but too many are deprived. God bless you and your wife.
It could be a trilogy like "The Godfather". It could show the first company trying to get something approved in 1906 with bags of cash (before brief cases) being given under the table.
But Estrada appears to have gotten it very quickly.
CFO said on the call yesterday when talking about dividends that the only dividend to be paid is on the Preferred and according to Delaeare law dividends are not payable until there is positive equity in the company. Go listen.
Yes, it is the part where he talks about his disappointment in the FDA re Leronlimab.
Dr. Been hits the nail on the head re the FDA.
Thumbs up.
Thanks for the breakdown. I agree.
Alot of support in the 2.00 area. We need a red to green day.
It has been my experience that unless you are dealing with an Enron type situation where there is fraud involved, that stocks seldom go straight down or straight up. The further you stretch the rubber band the harder the snapback.
Fundamentally, any good news from PI, Canada or any other front will result in a move to 3.20-4.06
That does not mean that we couldnot eventually come back down after the rally. The chart needs work.
Best of luck to you.
Good to see you posting. Smart move. I have been in and out. I sold yesterday at 3+ and bought back today at 2.25 just for the oversold bounce that should come.
For a bottim look for capitulation volume and going from red to green. With RSI at 25 it could be soon.
As I said, support is 2.25 and resistance is 4.05. For traders I would be a buyer at 2.25 and a seller at 4.05. For long term holders it does not matter.
My hope was that the 200 day sma would hold at 4.05. That did not happen and now it needs work. The RSI is at 30 which is oversold short term. I posted charts on Twitter this morning (Friar Tuck). Support in the 2.25 area, resistance 4.00 (200 day sma). GLTA
Got this from Twitter, which was a link from Reddit.
Dr. Woodcock,
CytoDyn released its top-line results for severe/critical COVID-19 this weekend, and it was nothing short of phenomenal. As you’re likely well-aware, the trial achieved statistical significance by decreasing hospitalization by 6 days in intubated patients. When adjusted for age, leronlimab was the first drug ever to achieve a statistically significant mortality benefit (p=.03) in a randomized, placebo controlled trial.
You have the power, and I would argue the ethical obligation, to grant an EUA based on this data. That decision is yours - and yours alone. Almost 540,000 Americans have died in this pandemic. How many of them could leronlimab have saved? How many of the more than 40,000 hospitalized today could benefit from leronlimab? The data unequivocally suggests leronlimab could save a lot of lives.
Moreover, the decision to grant an EUA based on age-adjusted and subgroup data isn’t unfounded. In the RECOVERY trial, the data for Decadron was age-adjusted and parsed into subgroups (intubated, oxygen, no oxygen) for its landmark data which is now the standard of care. Also, note that the RECOVERY trial was open-label.
CytoDyn’s trial of leronlimab was double-blinded, placebo (SoC) controlled and showed statistically significant benefits in mortality for critically ill patients and mortality benefit across the entire trial population in combination with Decadron (when age-adjusted), and length of stay in intubated patients was statistically significant even without the adjustment. Through no fault of its own, the age imbalance between trial arms (DSMC should have caught this) is literally now a life or death unfortunate event.
You have openly said that you don’t think people should die for a p-value. However, that’s exactly what you’re allowing right now by not issuing an EUA for leronlimab. I implore you to re-evaluate that decision and appeal to your humanity. Would you want your family member to get leronlimab if intubated or the current standard of care? I would want leronlimab.
As an emergency physician, I’ve admitted hundreds of patients - many of them to die - without any hope that they would live. Leronlimab gives those patients hope. It gives families hope. It gives me hope. But, for that hope to become reality, it is desperately needed for an EUA to be issued.
I beg you to issue the EUA. I don’t want any more of my patients to die without the hope leronlimab will provide to them and their families.
Respectfully,
John Bream, MD, FACEP
Dr. Woodcock's Twitter handle is @DrWoodcockFDA
I will tweet her also.
Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung
Transplantation Program, commented, “The CD12 trial results are very promising
and leronlimab may be the only safe medication to help critically ill
patients.”
Rock, do you mind if I share this on Twitter?
DANG, that is a bold statement. But I would not let possible corruption in areas you can not control dictate the waste of years of education and helpful healing to those in need of it.